近期中国资产Newco出海中规模最大的并购交易之一。 本文为IPO早知道原创 作者｜ Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，Ouro Medicines与Gilead Sciences（吉利德科学，NASDQ：GILD）于3月 24日签署并购协议，Gilead Sciences将通过并购方式收购Ouro Medicines，交易金额包括16.75 亿美元首付款（可按惯例调整）和最高5亿美元里程碑付款，总交易金额可达21.75亿美元。此外， Gilead Sciences拟就Ouro相关药物组合与Galapagos建立战略合作。 值得一提的是， 这是近期中国资产Newco出海 中规模最大 的并购交易之一。 Ouro Medicines由Monograph Capital与葛兰素史克（GSK）合作创立，是一家为慢性免疫介导 疾病患者开发免疫重治疗法的生物技术公司，名字源自象征重生的"ouroboros"（衔尾蛇），寓意 通过T细胞接合器（T-cell engagers, TCE）来实现免疫系统的"重置"，为自免疾病患者结束免疫 抑制药物的"无尽循环"， Ouro Medic ...

Financial Data and Key Metrics Changes - For the full year 2025, the company reported a net income of $1.23 billion and diluted earnings per share of $25.48, reflecting significant appreciation in treasury and treasury-related assets [3][11] - The company ended the year with $2.31 billion in total treasury and treasury-related assets and $1.93 billion in shareholders' equity, indicating strong financial positioning [11][12] Business Line Data and Key Metrics Changes - The clinical platform, particularly Allocetra, has shown clinically meaningful and statistically significant results, with a favorable safety profile, advancing towards late-stage development in osteoarthritis and other inflammatory indications [9][15] - The treasury strategy is designed to capture value from the emerging prediction markets economy, which is expected to grow significantly [4][12] Market Data and Key Metrics Changes - The prediction markets ecosystem is evolving, with increasing trading volumes and institutional engagement, positioning the company to capture early structural momentum [4][12] - The RAIN token, as a primary digital treasury reserve asset, is expected to benefit from the growth of decentralized prediction markets, enhancing long-term shareholder value [13][14] Company Strategy and Development Direction - The company is focused on a dual-engine model that integrates clinical development with a treasury strategy aligned with the growth of prediction markets [3][10] - The strategic partnership with the Rain Foundation allows the company to acquire RAIN tokens at a fixed price, enhancing its capital structure and growth potential [5][7] Management's Comments on Operating Environment and Future Outlook - Management believes that the current results are not isolated but represent the beginning of a broader shift towards institutional adoption of prediction markets [24] - The company aims to continue scaling its treasury strategy and advancing clinical programs, with a focus on capturing value across both scientific innovation and financial infrastructure [17][28] Other Important Information - The company announced a $21 million debt financing agreement to fund clinical development and acquire additional RAIN tokens at a discount [7][8] - A share repurchase program was approved to acquire up to $20 million of outstanding ordinary shares, indicating confidence in the company's value [8] Q&A Session Summary Question: Why is Enlivex posting large profits for 2025 despite a downturn in crypto? - Management attributed the profits to the bullish market for prediction markets, specifically the RAIN token, which increased in value [20] Question: How to explain the market cap discount to treasury valuation? - Management noted that the overall crypto market has been out of favor, leading to net asset value discounts, but expects this to improve as the prediction market ecosystem grows [21] Question: Does this change how clinical-stage companies can be financed? - Management indicated that the funding landscape has changed, with earlier-stage biotech companies facing challenges, but Enlivex's model allows for self-funding through treasury asset appreciation [22][23] Question: Is this a one-off outcome or the beginning of a broader shift? - Management sees this as the beginning of a broader shift towards public companies providing exposure to prediction markets [24] Question: How should investors view Enlivex after these results? - Management believes investors will now pay more attention to both sides of the dual model strategy following the earnings report [26] Question: What are the key drivers for scaling this model? - Management identified the growth of the prediction markets ecosystem and the advancement of the clinical program as key drivers for scalability [27]

Financial Data and Key Metrics Changes - For the full year 2025, the company reported a net income of $1.23 billion and diluted earnings per share of $25.48, reflecting a significant appreciation in treasury and treasury-related assets [3][11] - The total treasury and treasury-related assets reached $2.31 billion, with shareholders' equity at $1.93 billion, indicating strong financial positioning [11][12] Business Line Data and Key Metrics Changes - The company operates a dual-engine model combining clinical development with a treasury strategy focused on prediction markets, which is expected to drive long-term value [3][10] - The clinical platform, particularly Allocetra, has shown clinically meaningful results and is advancing towards late-stage development in osteoarthritis, with FDA clearance for a phase IIb trial [9][15] Market Data and Key Metrics Changes - The prediction markets ecosystem is experiencing structural momentum, with increasing trading volumes and institutional engagement, positioning the company to capture early opportunities [12][14] - The RAIN token, as a primary digital treasury reserve asset, is expected to benefit from the growth of decentralized prediction markets, enhancing long-term shareholder value [13][14] Company Strategy and Development Direction - The company aims to establish itself as a leader in a new category of public companies that integrate scientific innovation with financial infrastructure [10][17] - A strategic partnership with the Rain Foundation allows the company to acquire RAIN tokens at a fixed price, enhancing its capital structure and growth potential [5][8] Management's Comments on Operating Environment and Future Outlook - Management believes the current results are indicative of a broader shift towards institutional adoption of prediction markets, with expectations for continued growth in this sector [24][27] - The company is focused on scaling its treasury strategy and advancing clinical programs, with a commitment to leading the convergence of biology and finance [17][28] Other Important Information - The company announced a $21 million debt financing agreement to support clinical development and acquire additional RAIN tokens [7][8] - A share repurchase program was approved to acquire up to $20 million of outstanding shares, reflecting confidence in the company's value [8] Q&A Session Summary Question: Why is Enlivex posting large profits for 2025 despite a downturn in crypto? - Management attributed the profits to the bullish market for prediction markets, specifically the RAIN token, which increased in value [20] Question: How to explain the market cap discount to treasury valuation? - Management noted that the overall crypto market is out of favor, leading to net asset value discounts, but expects this to improve as the prediction market ecosystem grows [21] Question: Does this change how clinical-stage companies can be financed? - Management indicated that the funding landscape has shifted, with earlier-stage biotech companies facing challenges, but Enlivex's model allows for self-funding through treasury asset appreciation [22][23] Question: Is this a one-off outcome or the beginning of a broader shift? - Management sees this as the beginning of a broader shift towards public companies providing exposure to prediction markets [24] Question: How should investors think about Enlivex after these results? - Management believes investors will now pay more attention to the dual model strategy following the earnings report [26] Question: What are the key drivers for scaling this model? - Management identified the growth of the prediction markets ecosystem and the success of the clinical program as key drivers for scalability [27]

Core Insights - McKinsey's report identifies 18 industry sectors likely to reshape the global business landscape, predicting revenues of $29 trillion to $48 trillion by 2040, contributing 18-34% to global GDP growth [2] E-commerce - By 2040, e-commerce's share of global retail revenue could reach 27%-38%, up from approximately 20% currently [3] - Growth drivers include market expansion in developing countries and new product categories in developed nations, such as healthcare and emotionally valuable products [4] - Significant investments are expected in customer acquisition and last-mile delivery across e-commerce platforms [5] Electric Vehicles - Electric vehicles (EVs) are projected to exceed 50% of global passenger car sales by 2040 [6] - Breakthroughs in battery technology and smart algorithms will significantly influence this sector, prompting increased R&D investments from both EV manufacturers and traditional automakers [7] Cloud Services - The demand for storage and computing power is rising as the world becomes more interconnected, with new AI products requiring substantial computational resources [9] - The cloud services industry experienced a 17% compound annual growth rate from 2005 to 2020, with similar growth expected in the coming decades [10] Semiconductors - Semiconductors are foundational to the digital world, with demand from various sectors driving rapid growth [11] - The semiconductor industry is expected to maintain a 6%-8% compound annual growth rate over the next decade [11] AI Software Services - The rapid development of AI has led to its classification as a distinct sector, with increasing usage of AI assistants [12] - Companies in the AI space are engaged in a competitive race to develop advanced foundational models and applications [13] Digital Advertising - Digital advertising, through search, social media, and media platforms, is expanding in value as internet usage among the middle class increases [14] - Continuous algorithm improvements enhance platforms' abilities to target customers and track advertising costs, although competition for user attention drives platforms to invest heavily in engaging content [15] Streaming Video - Increased investment in customer acquisition and content production may lead streaming platforms to seek new revenue models [17] - Developing countries are expected to contribute to growth in subscription and advertising revenue for streaming services, with projections of over 1 billion households subscribing to long-form video services by 2040 [18] Shared Autonomous Vehicles - The advent of autonomous driving technology may reduce the necessity for personal vehicle ownership [19] - By 2040, shared autonomous vehicles could account for 25%-51% of shared mobility revenue [20] Space Economy - The world is on the brink of entering a space economy era, with advancements in reusable rocket technology changing the aerospace industry [21][22] Cybersecurity - Cybercrime caused approximately $950 billion in direct economic losses in 2020, with indirect losses potentially reaching $4-6 trillion [24] - Increasing awareness of cybersecurity has led businesses to invest more in enhancing their security measures [25] Batteries - Significant advancements in battery technology have tripled energy density over the past few decades [26] - The global energy transition is driving demand for batteries, particularly in electric vehicles, energy storage, and consumer electronics, with EVs expected to represent over 80% of the battery market by 2040 [28] Video Games - By 2030, an estimated 40% of the global population may become video game players [30] - New gaming models, such as mobile and cloud gaming, are accelerating market growth, with free-to-play games generating substantial revenue [32] Robotics - The integration of AI with robotics is creating significant expectations for humanoid robots as potential "ultimate intelligent agents" [33] Industrial and Consumer Biotechnology - Advances in gene editing and other technologies are accelerating the application of biotechnology in agriculture, alternative proteins, consumer products, and bio-materials [37] Modular Construction - Modular construction methods, which involve prefabricating building components, can significantly enhance construction efficiency [38] Nuclear Fission Power - The development of safer, smaller modular reactors may supplement renewable energy sources [39] Air Traffic - Electric vertical takeoff and landing vehicles and delivery drones represent major technological shifts in air traffic [41] Obesity Treatment Drugs - The prevalence of obesity is projected to rise from 15% in 2020 to 24% by 2035, indicating a potential market for effective weight loss products [43]

Investment Rating - The report initiates coverage on Baiaosaitu (2315.HK) with a "Buy" rating and sets a target price of HKD 66.90, indicating a potential upside of 37.65% from the current price of HKD 48.60 [4][6][7]. Core Insights - Baiaosaitu is a technology-driven biotechnology company focused on gene editing, aiming to become a global source of new drugs. Its core business is divided into two main lines: preclinical products and services, and antibody molecule transfer and development, with the latter being highlighted by the "Thousand Mice, Ten Thousand Antibodies" program [2][16]. - The preclinical business is experiencing robust growth, benefiting from the enthusiasm for innovative research. In the first half of 2025, the preclinical products and services generated revenue of CNY 458 million, with innovative model animal sales increasing by 56% year-on-year [3][28]. - The "Thousand Mice, Ten Thousand Antibodies" business model, which includes upfront payments, milestone payments, and revenue sharing, is entering a harvest period, significantly shortening research and development timelines and improving clinical success rates [3][4]. Company Analysis - Baiaosaitu's preclinical products and services are expected to achieve revenues of CNY 1.86 billion and CNY 2.35 billion in 2026 and 2027, respectively, with year-on-year growth rates of 34.8% and 26.5% [4][5]. - The company has established a high barrier to entry with its innovative model animal sales, which are projected to grow from CNY 660 million in 2020 to CNY 389 million in 2024, reflecting a CAGR of 55.9% [17][18]. - The antibody development business is also on a growth trajectory, with revenues expected to rise from CNY 410 million in 2020 to CNY 318 million in 2024, achieving a CAGR of 66.8% [19][20]. Financial Forecast and Valuation - The report forecasts Baiaosaitu's revenue to reach CNY 1.86 billion in 2026 and CNY 2.35 billion in 2027, with gross margins of 76.68% and 77.53%, respectively [4][5]. - The net profit attributable to the parent company is projected to be CNY 331 million and CNY 500 million for 2026 and 2027, representing year-on-year growth of 91.4% and 51.0% [4][5]. - The current price corresponds to a 2026 PE ratio of 58 times, while the target price corresponds to a PE ratio of 80 times [4].

Investment Rating - The report initiates coverage on the company with a "Buy" rating and sets a target price of HKD 66.90, indicating a potential upside of 37.65% from the current price of HKD 48.60 [4][6][7]. Core Insights - The company, Baiaosaitu (2315.HK), is a technology-driven biotechnology firm focused on gene editing and aims to become a global source of new drugs. Its core business revolves around two main lines: preclinical products and services, and antibody molecule transfer and development through the "Thousand Mice, Ten Thousand Antibodies" program [2][16]. - The preclinical business is experiencing robust growth, benefiting from the enthusiasm for innovative research. In the first half of 2025, the preclinical products and services generated revenue of CNY 458 million, with innovative model animal sales reaching CNY 274 million, a year-on-year increase of 56% [3][28]. - The "Thousand Mice, Ten Thousand Antibodies" business model, which includes upfront payments, milestone payments, and revenue sharing, is entering a harvest phase, with expectations for significant revenue growth as the number of transferred antibody projects increases [3][4]. Summary by Sections Company Analysis - Baiaosaitu is positioned as a leading biotechnology company with a focus on gene editing technology, offering preclinical pharmacology and efficacy evaluation services, innovative model animal sales, and gene editing services [2][16]. - The antibody development business leverages the "Thousand Mice, Ten Thousand Antibodies" initiative to create a library of antibodies, providing licensing services that are expected to drive future growth [2][3]. Preclinical Business Growth - The preclinical pharmacology and efficacy evaluation services are expanding rapidly, with revenue projected to grow significantly due to the increasing demand for innovative research tools and services [3][28]. - The sales of model animals, particularly humanized mouse models, are a major revenue source, with sales expected to grow from CNY 66 million in 2020 to CNY 389 million in 2024, reflecting a CAGR of 55.9% [17][28]. Antibody Development - The antibody development segment is projected to grow from CNY 41 million in 2020 to CNY 318 million in 2024, with a CAGR of 66.8%, driven by the RenMice technology platform and a vast antibody library [19][20]. - The company has established a strong foothold in the overseas market, with international revenue increasing from CNY 91 million in 2020 to CNY 662 million in 2024, representing a CAGR of 64.3% [27][28].

Investment Rating - The report maintains a "Recommended" rating for the new materials industry [1]. Core Insights - The new materials sector is positioned as a crucial direction for the chemical industry, currently experiencing rapid growth in downstream demand. With policy support and technological breakthroughs, domestic new materials are expected to accelerate into a long-term growth phase. The report emphasizes that "one generation of materials leads to one generation of industries," highlighting the foundational role of the new materials industry in supporting other sectors [6][18]. Summary by Sections 1. Electronic Information Sector - Focus on semiconductor materials, display materials, and 5G materials [7]. - NVIDIA announced the full production of the world's first Co-Packaged Optics (CPO) switch, Spectrum X, which integrates photonic components directly onto chips, achieving a bandwidth of 409.6 Tb/s to support large-scale generative AI workloads [8][38]. - MediaTek, in collaboration with Microsoft Research, developed a next-generation Active Optical Cable using micro-sized Micro LED light sources, significantly enhancing transmission distance while maintaining high reliability [9][10]. 2. Aerospace Sector - Focus on PI films, precision ceramics, and carbon fibers [11]. - Successful launch of multiple satellites using the Kuaizhou-11 solid rocket, showcasing the capabilities of the rocket in commercial launch tasks [12]. 3. New Energy Sector - Focus on photovoltaic materials, lithium-ion batteries, proton exchange membranes, and hydrogen storage materials [13]. - In February 2026, the National Energy Administration issued 198 million green power certificates, with a significant portion attributed to wind and solar power generation [13]. 4. Biotechnology Sector - Focus on synthetic biology and scientific services [14]. - Research teams have developed a new type of artificial photosynthetic cell that allows industrial microorganisms to efficiently synthesize high-value chemicals using solar energy [16]. 5. Energy Conservation and Environmental Protection Sector - Focus on adsorption resins, membrane materials, and biodegradable plastics [17]. - The Ministry of Industry and Information Technology and other departments issued a plan to enhance the energy efficiency of energy-saving equipment, targeting key industries for energy conservation and carbon reduction [18]. Key Companies and Earnings Forecast - The report highlights several key companies with earnings forecasts for 2024 to 2026, including: - Ruihua Tai (688323.SH): EPS forecasted to improve from -0.32 in 2024 to 0.26 in 2026 [19]. - Guangwei Composite (300699.SZ): EPS expected to rise from 0.89 in 2024 to 0.97 in 2026 [19]. - Zhongfu Shenying (688295.SH): EPS projected to increase from -0.14 in 2024 to 0.23 in 2026 [19]. The report emphasizes the potential for the new materials industry to enter a prosperous cycle driven by downstream application sectors [18].

Hangzhou Diagens Biotechnology Co., Ltd. 杭州德適生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司、香港聯合交易所有限公司（「香港聯交所」）及香港中央結算有限公 司（「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 除本公告另有界定者外，本公告所用詞彙與杭州德適生物科技股份有限公司（「本公司」）所刊發 日期為2026年3月20日的招股章程（「招股章程」）所界定者具有相同涵義。 本公告僅供參考，並不構成任何人士收購、購買或認購本公司任何證券的要約或誘使作出要約 的邀請。本公告並非招股章程。有意投資者於決定是否投資於發售股份前，務請細閱招股章 程，以獲得下文所述有關全球發售的詳細資料。任何有關發售股份的投資決定應僅依賴招股章 程所載的資料作出。 本公告概不構成要約出售或招攬要約購買發售股份，而在任何作出有關要約、招攬或出售即屬 違法的司法權區內，概不得出售任何發售股份。本公告不得直接或間接於或向美國或法律禁止 ...

Financial Data and Key Metrics Changes - The company ended 2025 with approximately $188 million in cash equivalents and marketable securities, providing a runway into 2028 to fund key clinical trials [18][17] - The financial position allows the company to provide top-line data in pivotal clinical trials, including the phase 2B trial in refractory chronic cough and the phase 3 trial in IPF-related chronic cough [18] Business Line Data and Key Metrics Changes - Trevi Therapeutics is preparing to initiate two pivotal phase 3 clinical trials for its lead indication, Haduvio, targeting IPF-related chronic cough, with plans to enroll approximately 300 patients in one trial and 130 in another [8][9] - The company is also planning a phase 2B trial for non-IPF interstitial lung disease (ILD) chronic cough, estimating a patient population of approximately 228,000, with 50%-60% having uncontrolled cough [11][12] Market Data and Key Metrics Changes - In the US, there are approximately 150,000 IPF patients, with two-thirds experiencing uncontrolled chronic cough, indicating a significant unmet medical need [10] - The market opportunity for non-IPF ILD chronic cough more than doubles that of IPF chronic cough, as these patients are primarily seen by the same pulmonologists [12] Company Strategy and Development Direction - The company aims to become a leader in chronic cough therapies, focusing on providing solutions for patients with high unmet needs [16] - Trevi is actively preparing for an investor and analyst day to discuss clinical and commercial strategies, as well as recent commercial learnings [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clarity of the path forward for the registration trials following a positive end-of-phase 2 meeting with the FDA [6][7] - The company is optimistic about the enrollment demand for the IPF chronic cough pivotal study, noting increased awareness among physicians and patient advocacy groups [79][80] Other Important Information - The company plans to file for orphan drug designation this year, although there is skepticism about approval due to the broader applicability of the treatment [73] - Trevi is preparing for significant presentations at the American Thoracic Society meeting, where new data from various trials will be shared [15][16] Q&A Session Summary Question: Can you elaborate on the remaining phase 1 studies? - The studies are label-informative, focusing on drug-drug interactions and metabolism, and will not be rate-limiting [20][22][23] Question: Any design features for the non-IPF ILD trial? - The design will leverage learnings from the IPF trial, focusing on dose-ranging and adaptive design [24][25] Question: Will there be any discussions about orphan drug designation? - The company plans to file for orphan drug designation after aligning with the FDA on the program [73] Question: What are the expectations for recruitment in the phase 3 IPF cough trial? - Enrollment is expected to take about a year, with 80 to 100 sites primarily in the US [102] Question: Will additional phase 1 drug-drug interaction studies be needed? - It depends on the timing of other drug approvals, but it is not seen as a barrier [104] Question: What is the anticipated placebo effect in the longer trial? - The company expects to be well-powered to handle the placebo response based on previous studies [97] Question: How will the company broaden the patient population for the phase 3 trial? - The trial will include patients on background anti-fibrotic medications and will not have a cough count requirement [120]

Option Therapeutics成立于2025年，计划在纽约证券交易所美国板(NYSE American)上市，股票代码为 OPTN。ThinkEquity担任该交易的独家账簿管理人。 该公司专注于开发治疗严重及危及生命的肝脏疾病的候选药物。其主导产品BIV201目前正被评估用于 治疗与晚期肝硬化相关的并发症，并已在美国、中国、日本、智利和印度提交专利申请。Option Therapeutics目前尚未产生收入。 周一，从BioVie分拆出来的临床二期肝病生物技术公司Option Therapeutics(OPTN.US)缩减了其即将进行 的IPO的规模。这家总部位于内华达州卡森城的公司现计划通过发行180万股、定价区间为10至12美元 的方式募资2000万美元。该公司此前曾申请以相同区间发行230万股。以发行价区间中值计算，Option Therapeutics的募资额将比此前预期减少20%。 ...